Skip to main content
Top
Published in: Journal of Assisted Reproduction and Genetics 11/2019

01-11-2019 | Infertility | Commentary

A 2019 reproductive update from the Midwest Reproductive Symposium International

Authors: Jessica R. Zolton, Gretchen G. Collins, Eleni A. Greenwood, Elie Hobeika, Roohi Jeelani, Angeline Beltsos, William G. Kearns

Published in: Journal of Assisted Reproduction and Genetics | Issue 11/2019

Login to get access

Abstract

“Mystery, Medicine, and the Magnificent Mile,” the theme for the annual Midwest Reproductive Symposium International (MRSi) in Chicago, IL, captured the attention of reproductive professionals all over the world. Each year, the conference agenda encompasses emerging technologies in assisted reproduction, updates in the management of reproductive diseases, and common challenges encountered in clinical practice. The structure of the meeting, offering a mixture of lectures, panel discussions, and interactive workshops, creates a collaborative environment for physicians, geneticists, embryologists, nurses, mental health professionals, basic scientists, business administrative professionals, reproductive endocrinology and infertility fellows, and obstetrics and gynecology residents. The goal of the MRSi meeting is to provide all reproductive professionals the opportunity to exchange ideas, foster relationships, and deliver quality patient care. As the field continues to evolve, MRSi provides an exciting venue to uncover the mysteries of reproductive medicine with enthusiasm and collaboration.
Literature
1.
go back to reference Calafat AM, et al. Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003-2004. Environ Health Perspect. 2008;116(1):39–44.CrossRef Calafat AM, et al. Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003-2004. Environ Health Perspect. 2008;116(1):39–44.CrossRef
2.
go back to reference Berman T, et al. Phthalate exposure among pregnant women in Jerusalem, Israel: results of a pilot study. Environ Int. 2009;35(2):353–7.CrossRef Berman T, et al. Phthalate exposure among pregnant women in Jerusalem, Israel: results of a pilot study. Environ Int. 2009;35(2):353–7.CrossRef
3.
go back to reference Ehrlich S, et al. Urinary bisphenol A concentrations and early reproductive health outcomes among women undergoing IVF. Hum Reprod. 2012;27(12):3583–92.CrossRef Ehrlich S, et al. Urinary bisphenol A concentrations and early reproductive health outcomes among women undergoing IVF. Hum Reprod. 2012;27(12):3583–92.CrossRef
4.
go back to reference Hauser R, et al. Urinary phthalate metabolite concentrations and reproductive outcomes among women undergoing in vitro fertilization: results from the EARTH Study. Environ Health Perspect. 2016;124(6):831–9.CrossRef Hauser R, et al. Urinary phthalate metabolite concentrations and reproductive outcomes among women undergoing in vitro fertilization: results from the EARTH Study. Environ Health Perspect. 2016;124(6):831–9.CrossRef
5.
go back to reference Kawamura K, et al. Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment. Proc Natl Acad Sci U S A. 2013;110(43):17474–9.CrossRef Kawamura K, et al. Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment. Proc Natl Acad Sci U S A. 2013;110(43):17474–9.CrossRef
6.
go back to reference Youssef MA, et al. A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF: a multicenter randomized non-inferiority trial. Hum Reprod. 2017;32(1):112–8.PubMed Youssef MA, et al. A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF: a multicenter randomized non-inferiority trial. Hum Reprod. 2017;32(1):112–8.PubMed
7.
go back to reference Bassiouny YA, et al. Does the addition of growth hormone to the in vitro fertilization/intracytoplasmic sperm injection antagonist protocol improve outcomes in poor responders? A randomized, controlled trial. Fertil Steril. 2016;105(3):697–702.CrossRef Bassiouny YA, et al. Does the addition of growth hormone to the in vitro fertilization/intracytoplasmic sperm injection antagonist protocol improve outcomes in poor responders? A randomized, controlled trial. Fertil Steril. 2016;105(3):697–702.CrossRef
8.
go back to reference Li XL, et al. The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96(12):e6443.CrossRef Li XL, et al. The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96(12):e6443.CrossRef
9.
go back to reference Teede HJ, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018;110(3):364–79.CrossRef Teede HJ, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018;110(3):364–79.CrossRef
10.
go back to reference Mejia RB, et al. A randomized controlled trial of combination letrozole and clomiphene citrate or letrozole alone for ovulation induction in women with polycystic ovary syndrome. Fertil Steril. 2019;111(3):571–578.e1.CrossRef Mejia RB, et al. A randomized controlled trial of combination letrozole and clomiphene citrate or letrozole alone for ovulation induction in women with polycystic ovary syndrome. Fertil Steril. 2019;111(3):571–578.e1.CrossRef
11.
go back to reference Marci R, et al. Presence of HHV-6A in endometrial epithelial cells from women with primary unexplained infertility. PLoS One. 2016;11(7):e0158304.CrossRef Marci R, et al. Presence of HHV-6A in endometrial epithelial cells from women with primary unexplained infertility. PLoS One. 2016;11(7):e0158304.CrossRef
12.
go back to reference Devine K, et al. Vitrified blastocyst transfer cycles with the use of only vaginal progesterone replacement with Endometrin have inferior ongoing pregnancy rates: results from the planned interim analysis of a three-arm randomized controlled noninferiority trial. Fertil Steril. 2018;109(2):266–75.CrossRef Devine K, et al. Vitrified blastocyst transfer cycles with the use of only vaginal progesterone replacement with Endometrin have inferior ongoing pregnancy rates: results from the planned interim analysis of a three-arm randomized controlled noninferiority trial. Fertil Steril. 2018;109(2):266–75.CrossRef
Metadata
Title
A 2019 reproductive update from the Midwest Reproductive Symposium International
Authors
Jessica R. Zolton
Gretchen G. Collins
Eleni A. Greenwood
Elie Hobeika
Roohi Jeelani
Angeline Beltsos
William G. Kearns
Publication date
01-11-2019
Publisher
Springer US
Published in
Journal of Assisted Reproduction and Genetics / Issue 11/2019
Print ISSN: 1058-0468
Electronic ISSN: 1573-7330
DOI
https://doi.org/10.1007/s10815-019-01594-8

Other articles of this Issue 11/2019

Journal of Assisted Reproduction and Genetics 11/2019 Go to the issue